Old prostate drug may spark brain cells in Parkinson's

NCT ID NCT07288450

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether terazosin, a drug currently used for an enlarged prostate, can boost energy production in brain cells of people with early Parkinson's disease. One hundred participants will receive either terazosin or a placebo for 6 months. Researchers will measure changes in energy molecules in the blood and brain to see if the drug hits its target.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Terazosin Hydrochloride
What this could lead to
If it works, this could point toward a treatment that slows Parkinson's by improving brain cell energy.
What could go wrong
This is a very early Phase 1/2 trial with only 100 people. It tests whether the drug hits its target in the body, not whether it improves symptoms. Many early trials do not lead to effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.